Ποια είναι η τιμή για Celltrion Healthcare Co., Ltd. (091990)

Η τιμή για Celltrion Healthcare Co., Ltd. (091990) είναι $57.75

Ποια είναι η κεφαλαιοποίηση αγοράς για Celltrion Healthcare Co., Ltd. (091990)

Η κεφαλαιοποίηση αγοράς για Celltrion Healthcare Co., Ltd. (091990) είναι $9.42B

Celltrion Healthcare Co., Ltd. (091990) Διαίρεση Μετοχών

Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.